Health & WellnessTech


Producing pharmaceutical-grade cannabinoids at 70-90% lower cost via biosynthesis
Investment type:
(Priced Round)
Target raise:
 - $1,069,998
Minimum investment:​
End date:
Dec 17, 2021
Share on facebook
Share on twitter
Share on linkedin
Share on email

  • 4 patents pending producing the best results in the market. Less than $1 a gram production costs per cannabinoid.
  • Producing 99% pharmaceutical grade, bioorganic, Non-GMO, 70-90% less than current wholesale prices
  • Successfully biosynthesized CBG/CBGA, THCV/THCVA and CBN/CBNA. Sustainably using 90% less resources
  • CGA benefits: reduces pain, inflammation; helps treat Inflammatory Bowel disease IDB, Glaucoma, Huntington’s disease
Our Story

Biosynthesis platform to produce 99% pharmaceutical grade cannabinoids, organic, 100% identical to natural cannabinoids at 70-90less cost using 90% less natural resources
Our Ambition

We want to dominate the multi-billion dollar market of rare cannabinoids and fuel the creation of new medical and wellness products leveraging the benefits of these powerful compounds.